Clinical trial
A Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of KM-819 in Healthy Older Adults and Participants with Parkinson's Disease
NCT05670782 is registered in ClinicalTrials.gov with FAScinate Therapeutics Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of KM-819 in Healthy Older Adults and Participants with Parkinson's Disease
- Lead sponsor
- FAScinate Therapeutics Inc.
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- July 19, 2022
- Completion date
- November 13, 2025
- Enrollment
- 314 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.